Synonym
Quinacainol; PK 10139; PK-10139; PK10139; RP 54272; RP-54272; RP54272; Quinacainol HCl
IUPAC/Chemical Name
1-(2-(tert-butyl)quinolin-4-yl)-3-(piperidin-4-yl)propan-1-ol dihydrochloride
InChi Key
JBFXAZXAVFRMKF-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H30N2O.2ClH/c1-21(2,3)20-14-17(16-6-4-5-7-18(16)23-20)19(24)9-8-15-10-12-22-13-11-15;;/h4-7,14-15,19,22,24H,8-13H2,1-3H3;2*1H
SMILES Code
Cl.Cl.CC(C)(C)C1=NC2=C(C=CC=C2)C(=C1)C(O)CCC3CCNCC3
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
399.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Pugsley MK, Walker MJ, Saint DA. Block of NA+ and K+ currents in rat ventricular myocytes by quinacainol and quinidine. Clin Exp Pharmacol Physiol. 2005 Jan-Feb;32(1-2):60-5. PubMed PMID: 15730436.
2: Howard PG, MacLeod BA, Walker MJ. Quinacainol, a new antiarrhythmic with class I antiarrhythmic actions in the rat. Eur J Pharmacol. 1992 Aug 14;219(1):1-8. PubMed PMID: 1397036.
3: Penz W, Pugsley M, Hsieh MZ, Walker MJ. A new ECG measure (RSh) for detecting possible sodium channel blockade in vivo in rats. J Pharmacol Toxicol Methods. 1992 Mar;27(1):51-8. PubMed PMID: 1316193.
4: Drobinski G, Montalescot G, Krumenacker M, Moussallem N, Grosgogeat Y. Haemodynamic effects of intravenous quinacainol with and without autonomic nervous system blockade. Int J Cardiol. 1991 Mar;30(3):341-7. PubMed PMID: 1676019.
5: Drobinski G, Montalescot G, Moussallem N, Krumenacker M, Grosgogeat Y. [Hemodynamic effects of quinacainol administered via an intravenous route. Study in patients with normal left ventricular function]. Therapie. 1990 Mar-Apr;45(2):119-23. French. PubMed PMID: 2191468.
6: Howard PG, Walker MJ. Electrical stimulation studies with quinacainol, a putative 1C agent, in the anaesthetised rat. Proc West Pharmacol Soc. 1990;33:123-7. PubMed PMID: 2274522.
7: Jaillon P, Drici M. Recent antiarrhythmic drugs. Am J Cardiol. 1989 Dec 5;64(20):65J-69J. Review. PubMed PMID: 2688391.
8: Voigt W, Mannhold R, Limberg J, Blaschke G. Interactions of antiarrhythmics with artificial phospholipid membranes. J Pharm Sci. 1988 Dec;77(12):1018-20. PubMed PMID: 3244104.
